Nationalizing Efavirenz: Compulsory License, Collective Invention, and Neo-developmentalism in Brazil (2001–2012) (notice n° 453534)
[ vue normale ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 01646cam a2200229 4500500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250121031658.0 |
| 041 ## - LANGUAGE CODE | |
| Language code of text/sound track or separate title | fre |
| 042 ## - AUTHENTICATION CODE | |
| Authentication code | dc |
| 100 10 - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Cassier, Maurice |
| Relator term | author |
| 245 00 - TITLE STATEMENT | |
| Title | Nationalizing Efavirenz: Compulsory License, Collective Invention, and Neo-developmentalism in Brazil (2001–2012) |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Date of publication, distribution, etc. | 2013.<br/> |
| 500 ## - GENERAL NOTE | |
| General note | 21 |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | This article examines the legal, technological, and industrial trajectory of an antiretroviral drug, Efavirenz, distributed freely to HIV/AIDS patients by the Brazilian Ministry of Health since the early 2000s. In May 2007, a presidential decree suspended the exclusive rights of the patent owner, Merck and Company, Inc., to exploit the molecule in Brazil, and authorized the production of a generic version by local laboratories. This compulsory license by the Brazilian government also intended to perpetuate the policy of universal access to treatment, with the objective of combating the AIDS epidemic and boosting the country's pharmaceutical industry. The nationalization of Efavirenz has allowed for experimental collective production in the form of an industrial consortium, and launched a policy of partnerships between public and private pharmaceutical laboratories. |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | public/private partnership |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | reverse engineering |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | collective invention |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | compulsory licence |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | generic medicine |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Corrêa, Marilena |
| Relator term | author |
| 786 0# - DATA SOURCE ENTRY | |
| Note | Autrepart | o 63 | 4 | 2013-05-17 | p. 107-122 | 1278-3986 |
| 856 41 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://shs.cairn.info/journal-autrepart-2012-4-page-107?lang=en&redirect-ssocas=7080">https://shs.cairn.info/journal-autrepart-2012-4-page-107?lang=en&redirect-ssocas=7080</a> |
Pas d'exemplaire disponible.
Réseaux sociaux